"Making Science Computable"

The Covid-19 Knowledge Accelerator is now the Health Evidence Knowledge Accelerator!

• Content and support tools for making science computable and facilitating HEvKA projects can be found on the Fast Evidence Interoperability Resources (FEvIR) Platform.

• The FEvIR HEvKA Project Page can be found at https://fevir.net/resources/Project/29272 and includes examples of evidence-related resources in current (R5) FHIR format.

Click on the images below to be redirected to each 3 minute lightening talk!

Google Drive folder for COKA

Click on the images below for introductory information about HEvKA

• Email balper@computablepublishing.com to be added to the HEvKA distribution list (daily email update of HEvKA activities)

• Join an expert working group for code system development -- see Invitation to join Expert Working Group. 

• Join us at any of the meetings listed on the left side of the screen by clicking on the following link: 

  Join Microsoft Teams Meeting (see meeting schedule below)

• We look forward to seeing you there!

You are welcome to join us!

Please email balper@computablepublishing.com with any questions.

For all of the above meetings: Join Microsoft Teams Meeting

+1 929-346-7156   United States, New York City (Toll)

Conference ID: 324 918 025#

Local numbers

Meeting support by Computable Publishing LLC

• Monday, May 15:

  • 8 am Eastern: Project Management – review IG preparations and FHIR Trackers
  • 9 am Eastern: Setting the SRDR Platform on FHIR Working Group – review FEvIR®: SRDR+ Project Importer and SRDR+ progress
  • 10 am Eastern: ResearchOnFHIR Working Group – continue learning about CQL
  • 2 pm Eastern: Statistic Standard and Terminology – draft SEVCO terms to match StatisticalModel Profile example; attention to Standard Deviation terms

  Tuesday, May 16:

  • 9 am Eastern: Measuring the Rate of Scientific Knowledge Transfer Working Group – review pilot efforts of investigator team
  • 2 pm Eastern: Research Design Working Group – draft EndpointAnalysisPlan Profile for future 'Research Protocol Implementation Guide'
  • 4 pm Eastern: HL7 Biomedical Research and Regulation (BRR) Work Group - agenda to include analysis of Group changes for CohortDefinition Profile

  Wednesday, May 17:

  • 8 am Eastern: Knowledge Ecosystem Liaison Working Group – determined by participants

  Thursday, May 18:

  • 8 am Eastern: EBM Implementation Guide Working Group (HL7 CDS EBMonFHIR sub-WG) – SummaryOfFindings and SummaryOfNetEffect Profiles of Composition Resource
  • 9 am Eastern: Computable EBM Tools Development Working Group – review FEvIR®; Platform developments; SummaryOfFindings Profile related developments
  • 12 pm Eastern: HL7 Biomedical Research and Regulation Work Group - FHIR Representation of Eligibility Criteria for Clinical Trials project; analysis of Group changes for CohortDefinition Profile
  • 4 pm Eastern: Project Management – prepare weekly agenda

  Friday, May 19: (may be canceled due to travel to HL7 Work Group Meeting)

  • 8 am Eastern: GRADE Vocabulary Working Group – prepare for GRADE Working Group meeting
  • 9 am Eastern: Risk of Bias Terminology and Tooling Working Group – review SEVCO terms; attention to Attrition Bias and Confounding Covariate Bias
  • 10 am Eastern: Communications Working Group – publications (Study Design Terminology), presentations (ICBO 2023)
  • 12 pm Eastern: Eligibility Criteria Working Group – analysis of Group changes for CohortDefinition Profile; review of FEvIR®: Characteristic Builder/Viewer

  
  

• EXAMPLES showcasing current FHIR format include:
• Evidence Resource (meta-analysis finding) at https://fevir.net/resources/Evidence/55, corresponding Citation Resource at https://fevir.net/resources/Citation/58
• Evidence Resource (randomized trial finding) at https://fevir.net/resources/Evidence/7637, corresponding Citation Resource at https://fevir.net/resources/Citation/7638
• EvidenceReport Resource (“COKA-EBM Clinical Outcomes in ACTT-1 Remdesivir RCT EvidenceReport”) at https://fevir.net/resources/EvidenceReport/156 fully supported with 9 Evidence Resources, 7 EvidenceVariable Resources, 2 Group Resources, and 1 ActivityDefinition Resource
• EvidenceReport Resource (“Anticoagulation for Non-critically ill COVID-19 Multiplatform RCT EvidenceReport”) at https://fevir.net/resources/EvidenceReport/18816
• EvidenceReport Resource (“Anticoagulation for Non-critically ill COVID-19 Individual RCTs Table EvidenceReport”) at https://fevir.net/resources/EvidenceReport/18831
• EvidenceReport Resource (“Anticoagulation for Non-critically ill COVID-19 Summary of Findings from RCTs Table EvidenceReport”) at https://fevir.net/resources/EvidenceReport/18881